MindWalk Holdings Corp. (NASDAQ:HYFT) Stock Has Consensus Price Target of $5.00 According to Brokerages

Shares of MindWalk Holdings Corp. (NASDAQ:HYFT) have been given a consensus recommendation of “Moderate Buy” by the five research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $5.00.

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings upgraded MindWalk from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 28th. Finally, Zacks Research raised shares of MindWalk from a “strong sell” rating to a “hold” rating in a research report on Monday, September 21st.

MindWalk Price Performance

NASDAQ HYFT opened at $1.04 on Monday. MindWalk has a fifty-two week low of $0.99 and a fifty-two week high of $2.99. The stock’s 50-day moving average is $1.32 and its two-hundred day moving average is $1.39. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.75 and a current ratio of 1.84.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings results on Monday, September 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The company had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.25 million. MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%. Equities research analysts anticipate that MindWalk will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MindWalk stock. GSA Capital Partners LLP bought a new position in shares of MindWalk Holdings Corp. (NASDAQ:HYFT) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 34,525 shares of the company’s stock, valued at approximately $55,000. GSA Capital Partners LLP owned about 0.07% of MindWalk at the end of the most recent reporting period. 6.70% of the stock is owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.